Insmed Execs在公司股票上出售了数百万美元, 但分析师保持了“Moderate Buy”评级。 Insmed execs sold millions in company stock, but analysts maintain a "Moderate Buy" rating.

包括CFO Sara Bonstein、COO Roger Adsett和CEO William Lewis在内的Insmed公司经理最近出售了大量公司股票,总额达数百万美元。 Insmed Incorporated's executives, including CFO Sara Bonstein, COO Roger Adsett, and CEO William Lewis, have recently sold significant amounts of company stock, totaling millions of dollars. 尽管销售量如此,但大型投资者增加了其股权,分析师维持了“机动购买”共识,目标价格为85美元。 Despite these sales, large investors have increased their stakes, and analysts have maintained a "Moderate Buy" consensus with a target price of $85. 该公司是一家生物制药公司,开发稀有疾病的治疗方法,其第一种产品ARIKAYCE获准治疗肺病。 Insmed, a biopharmaceutical company, develops treatments for rare diseases, with its first product, ARIKAYCE®, approved for treating lung disease.